Literature DB >> 27742769

The chemokine CXCR2 antagonist (AZD5069) preserves neutrophil-mediated host immunity in non-human primates.

Mohib Uddin1, Catherine Betts2, Ian Robinson3, Anna Malmgren1, Charles Humfrey3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27742769      PMCID： PMC5286957          DOI： 10.3324/haematol.2016.152371

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

Review 1.  Neutrophils and immunity: challenges and opportunities.

Authors:  Carl Nathan
Journal:  Nat Rev Immunol       Date:  2006-03       Impact factor: 53.106

2.  Scavenging roles of chemokine receptors: chemokine receptor deficiency is associated with increased levels of ligand in circulation and tissues.

Authors:  Astrid E Cardona; Margaret E Sasse; Liping Liu; Sandra M Cardona; Makiko Mizutani; Carine Savarin; Taofang Hu; Richard M Ransohoff
Journal:  Blood       Date:  2008-03-17       Impact factor: 22.113

3.  Role of CXCR2 in cigarette smoke-induced lung inflammation.

Authors:  T H Thatcher; N A McHugh; R W Egan; R W Chapman; J A Hey; C K Turner; M R Redonnet; K E Seweryniak; P J Sime; R P Phipps
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2005-04-15       Impact factor: 5.464

4.  The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions.

Authors:  Stipo Jurcevic; Charles Humfrey; Mohib Uddin; Steve Warrington; Bengt Larsson; Christina Keen
Journal:  Br J Clin Pharmacol       Date:  2015-10-02       Impact factor: 4.335

Review 5.  Role of neutrophils in innate immunity: a systems biology-level approach.

Authors:  Scott D Kobayashi; Frank R DeLeo
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2009 Nov-Dec

Review 6.  Chemokines in pathology and medicine.

Authors:  M Baggiolini
Journal:  J Intern Med       Date:  2001-08       Impact factor: 8.989

7.  Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist.

Authors:  David J Nicholls; Katherine Wiley; Ian Dainty; Fraser MacIntosh; Caroline Phillips; Alasdair Gaw; Carina Kärrman Mårdh
Journal:  J Pharmacol Exp Ther       Date:  2015-03-03       Impact factor: 4.030

8.  CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.

Authors:  Stephen I Rennard; David C Dale; James F Donohue; Frank Kanniess; Helgo Magnussen; E Rand Sutherland; Henrik Watz; Susan Lu; Paul Stryszak; Elizabeth Rosenberg; Heribert Staudinger
Journal:  Am J Respir Crit Care Med       Date:  2015-05-01       Impact factor: 21.405

9.  Cloning and pharmacological characterization of CXCR1 and CXCR2 from Macaca fascicularis.

Authors:  R William Hipkin; Gregory Deno; Jay Fine; Yongliang Sun; Brian Wilburn; Xuedong Fan; Waldemar Gonsiorek; Maria T Wiekowski
Journal:  J Pharmacol Exp Ther       Date:  2004-03-17       Impact factor: 4.030

10.  A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis.

Authors:  Anthony De Soyza; Ian Pavord; J Stuart Elborn; David Smith; Heather Wray; Margareta Puu; Bengt Larsson; Robert Stockley
Journal:  Eur Respir J       Date:  2015-09-04       Impact factor: 16.671
View more
  6 in total

1.  The role of CXCR2 in acute inflammatory responses and its antagonists as anti-inflammatory therapeutics.

Authors:  Xiaoyu Zhang; Rongxia Guo; Hiroto Kambara; Fengxia Ma; Hongbo R Luo
Journal:  Curr Opin Hematol       Date:  2019-01       Impact factor: 3.284

Review 2.  Targets of Neutrophil Influx and Weaponry: Therapeutic Opportunities for Chronic Obstructive Airway Disease.

Authors:  Carina Kärrman Mårdh; James Root; Mohib Uddin; Kristina Stenvall; Anna Malmgren; Kostas Karabelas; Matthew Thomas
Journal:  J Immunol Res       Date:  2017-05-15       Impact factor: 4.818

Review 3.  NETopathic Inflammation in Chronic Obstructive Pulmonary Disease and Severe Asthma.

Authors:  Mohib Uddin; Henrik Watz; Anna Malmgren; Frauke Pedersen
Journal:  Front Immunol       Date:  2019-02-05       Impact factor: 7.561

4.  Distinct Spatio-Temporal Dynamics of Tumor-Associated Neutrophils in Small Tumor Lesions.

Authors:  Simon Sody; Mohib Uddin; Anika Grüneboom; André Görgens; Bernd Giebel; Matthias Gunzer; Sven Brandau
Journal:  Front Immunol       Date:  2019-06-25       Impact factor: 7.561

5.  CXCR2 Mediates Distinct Neutrophil Behavior in Brain Metastatic Breast Tumor.

Authors:  Simrit Safarulla; Ankit Madan; Fei Xing; Arvind Chandrasekaran
Journal:  Cancers (Basel)       Date:  2022-01-20       Impact factor: 6.575

6.  The effect of reparixin on survival in patients at high risk for in-hospital mortality: a meta-analysis of randomized trials.

Authors:  Giovanni Landoni; Alberto Zangrillo; Gioia Piersanti; Tommaso Scquizzato; Lorenzo Piemonti
Journal:  Front Immunol       Date:  2022-07-25       Impact factor: 8.786
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.